Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

HURA

HURA News

Newswire

17:08

TuHURA Biosciences Reports Unaudited Pro Forma Condensed Combined Financial Information

01:11

Maxim Group Maintains TuHURA Biosciences Buy Recommendation with 458.78% Upside Potential

14:31

TuHURA Biosciences: Maxim Group maintains Buy with PT reduced to $8 from $15.

07:15

TuHURA Biosciences Reports Q3 2025 Financial Results and Provides Corporate Update

07:04

TuHURA Biosciences reports Q3 results, initiates Phase 3 trial for Merkel cell carcinoma.

View More

About HURA

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More